07:00 , Oct 29, 2012 |  BioCentury  |  Emerging Company Profile

Regenesance: Stopping the MAC attack

Regenesance B.V. is developing mAbs against complement 6 that may halt nerve damage and provide a better safety profile than standard of care for the orphan neurological disease myasthenia gravis. The mAbs are in lead...
07:00 , Aug 27, 2001 |  BioCentury  |  Finance

Ebb & Flow

Most of the private companies that raised money in the first half of 2000 - when the genomics "revolution" was driving super-high octane valuations - bought about a year-and-a-half of cash, which would put them...
07:00 , Aug 15, 1994 |  BC Week In Review  |  Company News

Calgene other research news

The Davis, Calif., company announced expression in canola plants of a gene for producing high levels of 8- and 10-carbon medium-chain fatty acids. The Cuph-2 gene was taken from a wild plant, Cuphea hookeriana, which...